NYSE: TDG · TransDigm Group IncorporatedEnhanced Equity Research · June 14, 2026
Equity Research Report
Analysis by Joseph Lefcoe
Enhanced Equity Research — TransDigm Group Incorporated (TDG)
Aerospace Aftermarket MonopolistPrivate-Equity-Style CompounderDebt-Fueled Pricing Power Machine

TDG

TransDigm Group Incorporated — Enhanced Equity Research
Current Price
$1257.24
Market Cap
71.1B
52-Week High
1623.83
52-Week Low
1183.60
BUY
PT $1512
+20% upside · Med-High conviction

Compounder Quality, Levered Balance Sheet — Constructive at a Discount

TransDigm remains a best-in-class aerospace aftermarket compounder, with Q2 FY26 delivering net sales up 18% to $2.54B and adjusted EPS of $9.85, beating consensus, prompting management to raise full-year guidance (sales to ~$10.36B, adj. EPS to ~$39.52). The model's structural moat — proprietary, sole-source parts with recurring high-margin aftermarket revenue — drives a 52.6% EBITDA margin and 59% gross margin, among the best in industrials. The principal risk is the balance sheet: ~$28.1B net debt at roughly 5.5x EBITDA, which amplifies returns but leaves the equity sensitive to rates and demand shocks. With the stock at $1,257, well off its $1,624 52-week high and trading near ~29x forward EPS, the risk/reward is constructive but no longer cheap. We see a probability-weighted target near $1,512 (~20% upside), supported by a Buy consensus and capital-return optionality via special dividends and M&A.

Best-in-Class Margins on a Levered Balance Sheet — Q2 FY26 beat-and-raise; ~61% gross margin and 52.6% EBITDA margin offset by ~5.5x net leverage.

Revenue (TTM)
$9.5B
+15% YoY blended
Adj. EPS (TTM)
~$38.40
FY26 guide ~$39.52
Gross Margin
59.3%
26-wk FY26
EBITDA Margin
52.6%
Q2'26, As Defined
Net Debt / EBITDA
~5.5x
$28.1B net debt
Op. Cash Flow
$967M
26-wk FY26
Revenue Growth YoY
+18%
Q2'26 net sales
Forward P/E
~29x
FY26 adj. EPS

Quarterly Revenue Trend (Last 4 Quarters)

$2.24B
Q3'25
$2.44B
Q4'25
$2.29B
Q1'26
$2.54B
Q2'26

Aftermarket Compounding Plus Capital-Return Optionality

+18%
Q2'26 Revenue Growth
vs. prior-year quarter
52.6%
EBITDA Margin
As Defined, Q2'26
~$39.52
FY26 Adj. EPS Guide
raised $1.14 at midpoint
May 2026
Q2 FY26 Beat & Raise
EPS $9.85 vs. $9.38 est; sales +18% to $2.54B; FY26 guidance lifted across sales, EBITDA, and EPS.
Apr 2026
$2.2B Jet Parts / Victor Sierra Deal
Debt-financed acquisition of proprietary aerospace component makers extends the M&A compounding engine.
FY26
Aftermarket Demand Cycle
Commercial aftermarket and defense bookings remain the swing factor for organic growth and margin mix.
Capital Return
Special Dividend Optionality
TDG returned a record $90/share special dividend in Sept 2025; none in Q2'26, leaving capital-return optionality.
Aug 2026
Q3 FY26 Report (est.)
Next key catalyst; watch aftermarket organic growth, leverage trajectory, and any capital-return announcement.

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

FY+1 EPS Consensus$39.52
FY+2 EPS Consensus$44.10
PEG Ratio2.36
Forward P/E29.3x
EPS Revisions (90d)↑11 ↓1 (upward)
Guidance AccuracyHigh — consistent history of meeting or beating raised guidance

Earnings Surprise Track Record

Q3'25 Est: 9.43 Act: 9.60 1.8%
Q4'25 Est: 11.20 Act: 11.50 2.7%
Q1'26 Est: 8.95 Act: 9.15 2.2%
Q2'26 Est: 9.38 Act: 9.85 5.0%
Beat Rate100% (4 of last 4)

Insider Activity (90 Days)

Net Buying/Selling+$15.8M
Sell/Buy Ratio1:2 buy-skewed
Neutral
Director Robert Small bought ~$26.6M (47,851 shares) in open-market purchases — a strong conviction signal — partially offset by routine option-related selling from the Howley family trust and another director.

Relative Valuation vs. Competitors

CompanyP/EEV/RevRev GrowthGross Margin
TransDigm38.4x9.2x18.3%60.7%
HEICO59.2x8.5x18.8%38.6%
Curtiss-Wright54.8x5.1x12.1%37.2%
RBC Bearings54.9x8.7x18.3%44.4%
Howmet Aerospace68.9x11.4x14.2%30.7%
TransDigm trades at the lowest trailing P/E of the cohort (~38x) yet commands the group's best-in-class ~61% gross margin and EV/Sales near 9x, reflecting its proprietary, sole-source aftermarket model. Peers HEICO, Curtiss-Wright, RBC Bearings and Howmet all carry richer earnings multiples (55x-69x P/E) on thinner margins, so TDG's premium is most visible on cash-flow and margin quality rather than headline P/E.

Price Targets & Scenarios

ScenarioPrice TargetAssumptionsProbability
Bull$1,720Aftermarket organic growth sustains low-double-digits, EBITDA margin pushes toward 54%, a large accretive M&A deal closes, and a sizable special dividend re-rates the multiple to ~32x.30%
Base$1,520FY26 guidance met (~$10.36B sales, ~$39.52 adj. EPS), aftermarket/defense demand steady, leverage held ~5.5x, multiple stable near 29-30x forward EPS.50%
Bear$1,180Commercial aftermarket decelerates, defense budget pressure bites, refinancing lifts interest burden on $28B debt, and the premium multiple compresses toward 24x.20%

Probability-Weighted Target: $1,512 (+20.3% vs. $1,257.24)

$1,512
Weighted
Bull $1,72030%
Base $1,52050%
Bear $1,18020%

Analyst Consensus

Goldman Sachs
$1,684
Buy
Morgan Stanley
$1,660
Overweight
Jefferies
$1,575
Buy
RBC Capital
$1,350
Sector Perform
Consensus Buy across 23 analysts; average 12-month target ~$1,568 (range $1,200-$1,900), implying ~25% upside from $1,257.

Key Levels & Options Intelligence

S/RSupport & Resistance

52-Week High
$1,623.83
200-Day MA
$1,350.77
Key Resistance
$1,290.00
50-Day MA
$1,267.34
Current Price
$1,257.24
Key Support
$1,161.62
52-Week Low
$1,123.61

OptOptions & Sentiment

  • Beta (5Y): 0.92 — low market sensitivity; defensive aerospace aftermarket profile
  • Short Interest: ~1.2M shares, ~2.2% of float — modest bearish positioning
  • Put/Call Ratio: ~1.6 OI skew toward puts — cautious near-term hedging
  • Implied Volatility: Elevated on near-dated contracts; market pricing event/earnings move
  • 30d IV Rank: Mid-range (~45-55th percentile) vs trailing year
  • Options Skew: Downside-tilted — put premiums richer than calls
  • Avg Daily Volume: ~261,000 shares — moderate liquidity for a $70B+ cap name
  • RSI (14): ~52 — neutral; below 50-/200-day MAs signals consolidation

Systematic Conviction Score: 74/100 (Med-High)

80
Analyst Alignment
30%
100
FCF Visibility
25%
50
Catalyst Clarity
20%
45
Valuation Safety
15%
90
Mgmt Quality
10%
Elite aftermarket moat, 100% FCF visibility, and a top-tier capital-allocation track record support high conviction, but ~5.5x leverage and a premium ~29x forward multiple with only ~20% upside cap valuation safety and pull the score just below High.

Risk Assessment & Insider Signals

!Risk Factors

  • Extreme Financial Leverage: Net debt of ~$27.4B sits at 5.8x EBITDA, near the high end of management's 5-7x target. The model is built on debt-financed special dividends (latest $90/share) and the $2.2B Jet Parts/Victor Sierra deal added ~$2B more notes/loans. Refinancing risk rises if aftermarket cash flow softens or rates stay elevated.
  • Premium Valuation / Multiple Compression: Shares (~$1,257) trade at ~39x TTM and ~21x EV/EBITDA. While below the 5-yr median ~47x, any growth deceleration or risk-off rotation out of high-multiple compounders leaves little margin of safety. Consensus PT ~$1,560 already prices in continued high-teens organic growth.
  • Defense Budget & OEM Cyclicality: Roughly a third of sales are defense and OEM channels are cyclical. A continuing-resolution / sequestration scenario or a commercial OEM build-rate slowdown (Boeing/Airbus supply chain) would pressure the lower-margin OEM segment and slow install-base growth that feeds the aftermarket.
  • DoD Sole-Source Pricing Scrutiny: TransDigm has repeatedly been the subject of DoD Inspector General reports alleging excess profits on sole-source proprietary parts. Renewed Congressional / regulatory pressure or mandated price concessions and broader PMA competition could erode the pricing power at the core of the moat.
  • M&A Integration & Capital Deployment: The strategy depends on continuously acquiring proprietary aftermarket assets at accretive prices. The $2.2B Jet Parts/Victor Sierra deal and ~$7B deployed in FY25 raise the bar; a richly-priced or poorly-integrated acquisition, or a dry M&A pipeline forcing cash to sit idle, would dilute the PE-style return engine.
  • Key-Man / Founder Concentration: The decentralized, value-based operating system traces to founder/chairman W. Nicholas Howley. Succession depth and continuity of the disciplined acquisition culture are a tail risk kept in focus by routine Howley-trust option activity.

OOwnership & Insider Signals

  • Heavily Institutionalized (~97%): Institutions own roughly 97% of shares. Retail is ~2.5% and insider ownership is minimal, so the register is dominated by index funds and active large-caps.
  • Concentrated Top Holder: Capital Research >22%: Capital Research & Management controls over 22% across funds — unusually concentrated active conviction for a mega-cap.
  • Index Whales: BlackRock ~7.5%: BlackRock holds ~7.45%. Vanguard's reported position dropped to ~0% after an internal reorganization in Jan 2026, a mechanical shift rather than a fundamental sell.
  • Serial Special Dividends: Four special dividends in four years escalating from $18.50 to a record $90/share (Sept 2025), plus ~$600M buybacks; ~$7B total capital deployed in FY25 across M&A and returns.
  • PE-Style Capital Allocation: Explicit goal: deliver private-equity-fund-like returns with public-market liquidity. Capital is recycled into proprietary aftermarket M&A and debt-funded shareholder returns rather than a recurring ordinary dividend.
  • Large, Liquid Float: With minimal insider lock-up and ~97% institutional ownership across ~56M shares, the float is large and liquid, though the >22% Capital Research stake plus index concentration means a meaningful share of supply is sticky.

Quantified Risk Assessment

Severity Risk Factor Prob. PT Impact
High Extreme Financial Leverage 35% -18%
High Premium Valuation / Multiple Compression 40% -20%
Medium Defense Budget & OEM Cyclicality 30% -12%
Medium DoD Sole-Source Pricing Scrutiny 25% -10%
Medium M&A Integration & Capital Deployment 30% -8%
Low Key-Man / Founder Concentration 15% -7%

Summary

Rating
BUY
Conviction
Med-High
Price Target
$1512
Timeframe
12 mo
Upside
+20%
Position Size
3%-5%

Entry Strategy

1
Tranche 1 — 40%
~$1,260
Initiate near current levels; stock sits ~22% below its 52-week high with a Buy consensus and a fresh beat-and-raise.
2
Tranche 2 — 35%
~$1,165
Add at key support / the 52-week-low zone, improving the entry multiple and margin of safety.
3
Tranche 3 — 25%
~$1,090
Reserve for a deeper risk-off pullback or a leverage/defense-budget scare below prior lows.
IMPORTANT DISCLAIMER: This analysis is for educational and research purposes only. Not financial advice. Past performance does not guarantee future results. Consult qualified financial professionals before making investment decisions. All investments carry risk of loss. The information presented is based on publicly available data as of June 14, 2026.